Skip Navigation Links.
Collapse <span class="m110 colortj mt20 fontw700">Volume 12 (2024)</span>Volume 12 (2024)
Collapse <span class="m110 colortj mt20 fontw700">Volume 11 (2023)</span>Volume 11 (2023)
Collapse <span class="m110 colortj mt20 fontw700">Volume 10 (2022)</span>Volume 10 (2022)
Collapse <span class="m110 colortj mt20 fontw700">Volume 9 (2021)</span>Volume 9 (2021)
Collapse <span class="m110 colortj mt20 fontw700">Volume 8 (2020)</span>Volume 8 (2020)
Collapse <span class="m110 colortj mt20 fontw700">Volume 7 (2019)</span>Volume 7 (2019)
Collapse <span class="m110 colortj mt20 fontw700">Volume 6 (2018)</span>Volume 6 (2018)
Collapse <span class="m110 colortj mt20 fontw700">Volume 5 (2017)</span>Volume 5 (2017)
Collapse <span class="m110 colortj mt20 fontw700">Volume 4 (2016)</span>Volume 4 (2016)
Collapse <span class="m110 colortj mt20 fontw700">Volume 3 (2015)</span>Volume 3 (2015)
Collapse <span class="m110 colortj mt20 fontw700">Volume 2 (2014)</span>Volume 2 (2014)
Collapse <span class="m110 colortj mt20 fontw700">Volume 1 (2013)</span>Volume 1 (2013)
American Journal of Medical Case Reports. 2021, 9(2), 131-133
DOI: 10.12691/AJMCR-9-2-8
Original Research

Insulin Resistance One Mechanism Two Presentations: Olanzapine Induced DKA and Hypertriglyceridemia

Louis Costanzo1, , Chetana Pendkar1, Amara Shafi1 and Joseph Gorga2

1Department of Internal Medicine, State University of New York, Downstate- Health Science University, Brooklyn, NY, USA - 11203

2Division of Pulmonology, State University of New York, Downstate- Health Science University, Brooklyn, NY, USA - 11203

Pub. Date: December 20, 2020
Full Text PDF

Cite this paper

Louis Costanzo, Chetana Pendkar, Amara Shafi and Joseph Gorga. Insulin Resistance One Mechanism Two Presentations: Olanzapine Induced DKA and Hypertriglyceridemia. American Journal of Medical Case Reports. 2021; 9(2):131-133. doi: 10.12691/AJMCR-9-2-8

Abstract

Patients taking antipsychotic medications have a well-established increased risk of developing metabolic syndrome. These medications interfere with an intracellular signaling pathway leading to insulin resistance; that of which can lead to dangerous complications including diabetic ketoacidosis (DKA) and severe hypertriglyceridemia. We report a case of a 21-year-old man who developed DKA and severe hypertriglyceridemia secondary to the use of olanzapine used for the management of schizophrenia.

Keywords

atypical antipsychotics, critical care, diabetic ketoacidosis, hypertriglyceridemia, insulin resistance, metabolic acidosis, olanzapine

Copyright

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]  Uçok A, Gaebel W. Side effects of atypical antipsychotics: a brief overview. World Psychiatry. 2008; 7(1): 58-62.
 
[2]  Ball MP, Coons VB, Buchanan RW. A program for treating olanzapine-related weight gain. Psychiatr Serv. 2001; 52: 967-969.
 
[3]  Hirowatari Y, Yoshida H, Kurosawa H, Doumitu KI, Tada N. Measurement of cholesterol of major serum lipoprotein classes by anion-exchange HPLC with perchlorate ion-containing eluent. J Lipid Res. 2003; 44(7): 1404-1412.
 
[4]  Wilson DR, D'Souza L, Sarkar N, Newton M, Hammond C. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res. 2003; 59: 1-6.
 
[5]  De Meyts P. The Insulin Receptor and Its Signal Transduction Network. [Updated 2016 Apr 27]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK378978/.
 
[6]  Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry. 2003; 64(5): 598-604.
 
[7]  Weston-GreenK, Huang XF, Lian J, Deng C. Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels.Eur Neuropsychopharmacol. 2012; 22(5): 364-73.
 
[8]  Thomas K, Saadabadi A. Olanzapine. [Updated 2020 Jul 18]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532903/.
 
[9]  Generali JA, Cada DJ. Topiramate: antipsychotic-induced weight gain. Hosp Pharm. 2014; 49(4): 345-347.
 
[10]  Praharaj SK, Sharma PS. Amantadine for olanzapine-induced weight gain: a systematic review and meta-analysis of randomized placebo-controlled trials. Ther Adv Psychopharmacol. 2012; 2(4): 151-156.
 
[11]  van der Zwaal EM, Janhunen SK, Luijendijk MC, et al. Olanzapine and sibutramine have opposing effects on the motivation for palatable food. Behav Pharmacol. 2012; 23(2): 198-204.